Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Shares Outstanding (Diluted Average) (2019 - 2026)

Akebia Therapeutics has reported Shares Outstanding (Diluted Average) over the past 7 years, most recently at $257.2 million for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 21.91% to $257.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $257.2 million through Dec 2025, up 21.91% year-over-year, with the annual reading at $257.2 million for FY2025, 21.91% up from the prior year.
  • Shares Outstanding (Diluted Average) was $257.2 million for Q4 2025 at Akebia Therapeutics, down from $274.4 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $274.4 million in Q3 2025 and troughed at $153.8 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $187.9 million (2023), against an average of $200.4 million.
  • Year-over-year, Shares Outstanding (Diluted Average) dropped 2.4% in 2023 and then soared 30.44% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $165.9 million in 2021, then rose by 10.14% to $182.8 million in 2022, then rose by 2.56% to $187.5 million in 2023, then rose by 12.53% to $210.9 million in 2024, then rose by 21.91% to $257.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Shares Outstanding (Diluted Average) are $257.2 million (Q4 2025), $274.4 million (Q3 2025), and $271.1 million (Q2 2025).